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the hierarchical data structure: patients with prescribed statines,
nested in their prescribing general practitioner. The multilevel
model advantage lies on the fact that one can insert, in the same
analysis, independent variables related either to the general prac-
titioners (level-2) or to the patients (level-1). Furthermore, one
can quantify the variability at each level, which is, prescribing
practitioners’ variability and patients’ variability. Particularly, a
random intercept model has been built, where the response vari-
able is the sum of the daily dosages given in the prescriptions 
for each patient. Actually, we refer to generalized linear model
theory, because the dependent variable is Gamma-distributed.
RESULTS: The regressors referred to the patients (level-1) and
inserted into the model are: age, sex, and use of other cardio-
vascular drugs. The level-2 independent variables, hence referred
to practitioner, are: age, sex, specialization (yes/no) on cardiol-
ogy, ratio of statines’ prescriptions on total number of prescrip-
tions of cardiovascular drugs and percentage of patients over 65
years old. The largest part of variability is obviously due to
patients’ effect. Regarding the regressions of level 2, the age of
the practitioner provides a negative and signiﬁcant coefﬁcient,
indicating a tendency towards “prescriptive thrift” by older
doctors. CONCLUSIONS: It appears to be a clear evidence that
the consumption of statines and, generally, of drugs cannot be
simply reduced to individual characteristics. From a method-
ological point of view, it has been shown that multilevel
approach provides a coherent framework, in spite of the lack of
applications to health sciences.
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While treatment guidelines recommend lowering cholesterol to
target levels, many remain above goal (LDL-C >100mg/dL for
CHD and diabetic patients and LDL-C >130mg/dl for other 
non-CHD high risk individuals). OBJECTIVE: To project the
change in LDL-C and goal attainment rates by treating patients
with Ezetimibe/Simvastatin 10/20mg, and compare it with what
was observed in clinical practice with statin monotherapy.
METHOD: A decision-analytic model was developed to project
goal attainment at end of one year after therapy change. Short
term clinical trial data were used to estimate LDL-C reductions
for Ezetimibe/Simvastatin therapy. The model was run for a pop-
ulation of 504 Spanish patients (237 CHD/diabetic and 267 non-
CHD high risk patients) that had not reached LDL-C goal levels
3 months after starting statin therapy. Patients were assumed to
remain treated with Ezetimibe/Simvastatin 10/20mg for 12
months from then, and their results compared with those
observed in real life in the same time period. RESULTS: Mean
age of study population was 60.8 (SD 9.8) years, 47.8% female,
lipid proﬁle (mg/dl) at three months on statin monotherapy was
LDL-C 182.3 (SD 35.1), TC 262.1 (SD 39.5), HDL-C 50.8 (SD
14.1), triglycerides 150.1 (SD 82.5). Ezetimibe/Simvastatin
10/20mg. therapy is projected to achieve a 53.4% goal attain-
ment rate, were as a 2.0% goal attainment rate was observed in
clinical practice (were 8% of patients were up titrated on statin
dose during ﬁrst year). With respect to LDL-C reductions, Eze-
timibe/Simvastatin 10/20mg. could achieve a 31.5% reduction
over baseline, vs. a 4.9% achieved in real life clinical practice
during similar time period. CONCLUSION: Treating patients
not at goal on statin monotherapy with Dual-inhibition therapy
(Ezetimibe/Simvastatin 10/20mg) is projected to greatly improve
the results of lipid-lowering therapy compared to statin
monotherapy observed in real life clinical practice.
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OBJECTIVES: The relationship between compliance and persis-
tence with hypertension therapies and clinical outcomes has 
not previously been quantiﬁed. In addition, little information is
available regarding the “real-world” effectiveness of hyperten-
sion therapies. In this study, we evaluated the impact of compli-
ance and persistence with valsartan (Diovan®) therapy on blood
pressure outcomes using ofﬁce-based effectiveness data.
METHODS: We analyzed data from the Geisinger Clinic, a U.S.
regional health care network with 52 primary care and specialty
clinics. Information on patient characteristics and longitudinal
data on prescribed medications and use and ofﬁce blood pres-
sure reading were obtained from the network’s electronic health
record database. Hypertension status was based on JNC VII
guidelines. RESULTS: Increased compliance with use of valsar-
tan therapy (i.e., taking therapy as prescribed) was associated
with a signiﬁcant decrease in systolic and diastolic blood pres-
sure 6 and 12 months after the initial prescription. At 12 months,
a 10% increase in compliance resulted in decreases in systolic
and diastolic blood pressure of 1.3 and 0.5mmHg (respectively)
and a 17% increase in having controlled blood pressure. Greater
persistence with valsartan therapy (i.e., time on therapy follow-
ing control of blood pressure) was also associated with signiﬁ-
cant decreases in blood pressure. For each additional month of
treatment persistence following blood pressure control, systolic
and diastolic blood pressure at one year decreased by 1.4 and
0.5mmHg, respectively. CONCLUSIONS: We have demon-
strated that both compliance and persistence with valsartan
therapy are associated with signiﬁcant improvements in blood
pressure control. Further, having access to ofﬁce-based blood
pressure data, we were able to evaluate treatment effectiveness
rather than only efﬁcacy. Improved compliance and persistence
with hypertension therapy is likely to result in long-term
improvement in patient outcomes, such as decreased cardiovas-
cular complications.
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Atorvastatin produces the highest cLDL reduction among the
statins commercialized in Spain, as demonstrated in clinical
trials. OBJECTIVE: To retrospectively compare the effectiveness
of different statins in terms of CVRF control, in daily clinical
practice. METHODS: A total of 9001 subjects from four
primary care centres in Catalonia were retrospectively examined.
A total of 9001 hypertensive and/or dyslipidemic patients from
Managed Care programmes were selected. The following vari-
ables were retrospectively compared for the different statins: 1)
the level of cardiovascular risk as deﬁned by ATP III criteria; 2)
average number of CVRF; and 3) average proportion of subjects
with appropriately controlled CVRF according to ATP III crite-
ria. RESULTS: 1) The average proportion of patients with pre-
